Lexeo Therapeutics (NASDAQ:LXEO) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $20.00 target price on the stock. Several other analysts also recently weighed in on LXEO. Stifel Nicolaus began coverage on Lexeo […]

Leave a Reply

Your email address will not be published.

Previous post RLJ Lodging Trust (NYSE:RLJ) Upgraded at Oppenheimer
Next post Profound Medical (NASDAQ:PROF) Earns Hold Rating from Analysts at Stifel Nicolaus